Sareum Holdings soars 170% on pre-clinical CHK 1 study

Sareum Holdings (SAR) is currently up 170% on news from its CHK-1 inhibitor in Colon Cancer. Potential investors should remember that this is a very early stage pre-clinical study and secondly I would bet that Sareum have a fund raising on this news. I wouldn't be surprised to see it lower by the end of the day. Exciting stuff for investors who bought at 1p though. See my previous review on Sareum : http://contrarianinvestoruk.blogspot.com/2011/02/sareum-holdings-pharmaceutical-cancer.html

Research Update: Positive Chk1 Programme Model Studies

 (AIM: SAR)   4 March 2011


                              SAREUM HOLDINGS PLC
                                   ("Sareum")

             Research Update: Positive Chk1 Programme Model Studies
Sareum,  the specialist cancer  drug discovery business,  is pleased to announce
positive  results from  pre-clinical in-vivo  efficacy studies  from their joint
research  collaboration with Cancer Research  Technology Limited ("CRT") and The
Institute of Cancer Research ("The ICR").

A  recent  colon  cancer  pre-clinical  model  study  carried  out  by  The  ICR
demonstrates  that the combination of a  collaboration Chk1 inhibitor, dosed via
the   oral   route,   in   combination  with  a  chemotherapeutic,  gemcitabine,
demonstrates a greater than two-fold reduction in cancer growth rate compared to
treatment with the same dose of gemcitabine without the Chk1 inhibitor.

Further   pre-clinical   in-vivo   studies  for  the  programme  show  that  the
collaboration Chk1 inhibitor, dosed alone, can reduce cancer growth in models of
AML  (acute myeloid leukaemia) and  neuroblastoma (a childhood cancer).  Certain
cancers, such as these, are believed to be dependent on Chk1 for survival.

The  joint research collaboration with the  ICR and CTR targets Chk1 (Checkpoint
Kinase  1). Chk1 is  important in  controlling a  cancer cell's  response to DNA
damage, which may be a consequence of the cancer itself, or intentionally caused
by chemotherapy or radiotherapy.

Sareum's CEO, Dr Tim Mitchell, commented:

"These  are exciting advances,  demonstrating efficacy of  our Chk1 compounds in
several cancer models. Studies on additional models are on-going. We believe the
results  from  the  recently  conducted  studies  will significantly enhance the
licencing  package and assist  the collaboration in  selecting the best compound
for development into a clinical trials candidate".